(UHS) Universal Health - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 9.947m USD | Total Return: -17.7% in 12m
Avg Turnover: 180M
EPS Trend: 98.9%
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 1
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Universal Health Services, Inc. (UHS) is a major healthcare provider operating through two primary segments: Acute Care Hospital Services and Behavioral Health Care Services. Headquartered in Pennsylvania, the company manages a diverse portfolio of acute care hospitals, outpatient clinics, and behavioral health facilities across the United States. Its service offerings range from general surgery and emergency medicine to specialized pediatric and oncology care.
The company utilizes a vertically integrated business model, providing secondary support functions such as commercial health insurance, physician recruitment, and centralized financial control systems. Within the Health Care Facilities sub-industry, behavioral health remains a critical growth driver due to high barriers to entry and a persistent supply-demand imbalance for psychiatric beds. Unlike many specialized providers, UHS maintains a diversified revenue stream by balancing high-acuity surgical services with long-term behavioral health management.
For more detailed insights into the company’s valuation metrics, you may find it useful to explore ValueRay. Investors in this sector typically monitor regulatory reimbursement rates and labor costs as primary drivers of operational margins.
- Behavioral health facility occupancy rates drive long-term revenue and margin stability
- Labor cost volatility and nursing shortages impact acute care operating margins
- Medicaid reimbursement rate adjustments significantly influence annual net income projections
- Expansion of acute care service lines increases high-margin surgical procedure volume
- Regulatory scrutiny of behavioral health practices poses potential legal and financial risks
| Net Income: 1.52b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.40 > 1.0 |
| NWC/Revenue: 1.44% < 20% (prev 4.65%; Δ -3.21% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.91b > Net Income 1.52b |
| Net Debt (5.42b) to EBITDA (2.79b): 1.94 < 3 |
| Current Ratio: 1.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.7m) vs 12m ago -6.55% < -2% |
| Gross Margin: 71.32% > 18% (prev 0.90%; Δ 7.04k% > 0.5%) |
| Asset Turnover: 116.2% > 50% (prev 108.1%; Δ 8.12% > 0%) |
| Interest Coverage Ratio: 14.21 > 6 (EBITDA TTM 2.79b / Interest Expense TTM 152.5m) |
| A: 0.02 (Total Current Assets 3.50b - Total Current Liabilities 3.24b) / Total Assets 15.7b |
| B: 0.52 (Retained Earnings 8.20b / Total Assets 15.7b) |
| C: 0.14 (EBIT TTM 2.17b / Avg Total Assets 15.3b) |
| D: 1.93 (Book Value of Equity 15.7b / Total Liabilities 8.11b) |
| Altman-Z'' = 4.79 = AA |
| DSRI: 1.03 (Receivables 2.75b/2.41b, Revenue 17.8b/16.1b) |
| GMI: 1.26 (GM 71.32% / 90.13%) |
| AQI: -0.36 (AQ_t -0.12 / AQ_t-1 0.32) |
| SGI: 1.10 (Revenue 17.8b / 16.1b) |
| TATA: -0.02 (NI 1.52b - CFO 1.91b) / TA 15.7b) |
| Beneish M = -3.52 (Cap -4..+1) = AAA |
As of May 27, 2026, the stock is trading at USD 156.63 with a total of 858,950 shares traded.
Over the past week, the price has changed by -6.43%,
over one month by -12.09%,
over three months by -31.54% and
over the past year by -17.67%.
Universal Health has received a consensus analysts rating of 3.68. Therefore, it is recommended to hold UHS.
- StrongBuy: 6
- Buy: 2
- Hold: 10
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 221.4 | 41.4% |
P/E Trailing = 6.8581
P/E Forward = 7.0721
P/S = 0.5601
P/B = 1.3498
P/EG = 1.1594
Revenue TTM = 17.8b USD
EBIT TTM = 2.17b USD
EBITDA TTM = 2.79b USD
Long Term Debt = 3.95b USD (from longTermDebt, last quarter)
Short Term Debt = 829.1m USD (from shortTermDebt, last quarter)
Debt = 5.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 417.5m
Net Debt = 5.42b USD (calculated: Debt 5.54b - CCE 119.0m)
Enterprise Value = 15.4b USD (9.95b + Debt 5.54b - CCE 119.0m)
Interest Coverage Ratio = 14.21 (Ebit TTM 2.17b / Interest Expense TTM 152.5m)
EV/FCF = 17.19x (Enterprise Value 15.4b / FCF TTM 894.0m)
FCF Yield = 5.82% (FCF TTM 894.0m / Enterprise Value 15.4b)
FCF Margin = 5.03% (FCF TTM 894.0m / Revenue TTM 17.8b)
Net Margin = 8.56% (Net Income TTM 1.52b / Revenue TTM 17.8b)
Gross Margin = 71.32% ((Revenue TTM 17.8b - Cost of Revenue TTM 5.09b) / Revenue TTM)
Gross Margin QoQ = 14.64% (prev 90.58%)
Tobins Q-Ratio = 0.98 (Enterprise Value 15.4b / Total Assets 15.7b)
Interest Expense / Debt = 2.75% (Interest Expense 152.5m / Debt 5.54b)
Taxrate = 23.54% (110.4m / 469.1m)
NOPAT = 1.66b (EBIT 2.17b * (1 - 23.54%))
Current Ratio = 1.08 (Total Current Assets 3.50b / Total Current Liabilities 3.24b)
Debt / Equity = 0.74 (Debt 5.54b / totalStockholderEquity, last quarter 7.53b)
Debt / EBITDA = 1.94 (Net Debt 5.42b / EBITDA 2.79b)
Debt / FCF = 6.07 (Net Debt 5.42b / FCF TTM 894.0m)
Total Stockholder Equity = 7.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.95% (Net Income 1.52b / Total Assets 15.7b)
RoE = 20.93% (Net Income TTM 1.52b / Total Stockholder Equity 7.27b)
RoCE = 19.32% (EBIT 2.17b / Capital Employed (Equity 7.27b + L.T.Debt 3.95b))
RoIC = 12.61% (NOPAT 1.66b / Invested Capital 13.1b)
WACC = 6.45% (E(9.95b)/V(15.5b) * Re(8.88%) + D(5.54b)/V(15.5b) * Rd(2.75%) * (1-Tc(0.24)))
Discount Rate = 8.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.39 | Cagr: -4.56%
[DCF] Terminal Value 73.10% ; FCFF base≈959.0m ; Y1≈841.0m ; Y5≈679.5m
[DCF] Fair Price = 102.9 (EV 10.9b - Net Debt 5.42b = Equity 5.48b / Shares 53.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 98.88 | EPS CAGR: 37.99% | SUE: 0.44 | # QB: 0
Revenue Correlation: 99.90 | Revenue CAGR: 9.86% | SUE: 1.72 | # QB: 1
EPS current Quarter (2026-06-30): EPS=5.86 | Chg30d=-0.54% | Revisions=-20% | Analysts=12
EPS next Quarter (2026-09-30): EPS=5.65 | Chg30d=-2.79% | Revisions=-33% | Analysts=12
EPS current Year (2026-12-31): EPS=23.44 | Chg30d=-0.36% | Revisions=-7% | GrowthEPS=+7.8% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=25.40 | Chg30d=-0.78% | Revisions=+0% | GrowthEPS=+8.4% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -33%